EASL Podcasts

This EASL Studio episode examines the current relevance of Hepatic Encephalopathy (HE) and the roles of hepatologists and interventional radiologists in patient care. The discussion covers technical approaches, patient outcomes, and the expanding indications for TIPS.Tune in to:Learn about the critical roles of hepatologists and radiologists in managing HE.Understand technical factors, including TIPS procedures and their application in modern hepatology.Explore the use of TIPS for aging patients, those with variceal bleeding, and major surgery candidates.FacultyVirginia Hernández-Gea (Moderator)Dominique Thabut (Faculty)Dhiraj Tripathi (Faculty)Thomas Kröncke (Faculty)This EASL Studio is supported by an educational grant from Cook Medical. EASL has received no input from Cook Medical with regards to the content of this programme.Related episodesEASL Studio S6E11: Assessment of clinically significant portal hypertension in 2024 – Is it time to say goodbye to invasive measurements?EASL Studio S2E14: Elastography – The new non-invasive gold standard in portal hypertension?All EASL Studio Podcasts are available on EASL Campus.

Sarcopenia, defined by a reduction in muscle mass and strength, significantly increases the risk of hospitalisation and mortality in patients with liver cirrhosis. This EASL Studio episode highlights the importance of incorporating sarcopenia assessment and management into routine clinical practice. Experts discuss the optimal timing for assessment and strategies for implementing effective interventions.FacultyFelicity Williams (Moderator)Shelley Keating (Faculty)Jennifer Lai (Faculty)Jonathan Stine (Faculty)All EASL Studio Podcasts are available on EASL Campus.

This EASL Studio episode explores how alcohol worsens liver disease in patients with cardiometabolic risks, the stigma affecting diagnosis and care, and the latest therapeutic advances.Key topics of discussion include:Interaction between alcohol and cardiometabolic risksStigma and its impact on patient careIdentifying at-risk patients with clinical markersEmerging therapies and research opportunitiesFacultyAleksander Krag (Moderator)Fredrik Åberg (Faculty)Maru Rinella (Faculty)Maja Thiele (Faculty)This EASL Studio is supported by Boehringer Ingelheim. EASL has received no input from Boehringer Ingelheim with regards to the content of this programme.Related episodesEASL Studio S5E9: Alcohol and the new nomenclature – A game-changer?EASL Studio S4E8: The central role of alcohol and food policies on liver healthEASL Studio S4E3: A 360 approach to beat alcohol-related liver diseaseEASL Studio S3E5: JHEP Live: Stigma and alcoholAll EASL Studio Podcasts are available on EASL Campus.

Join the experts as they explore the new updates to the liver transplantation clinical practice guidelines, and delve into the latest advancement and ongoing challenges faced in this field.Tune in to:Discover cutting-edge techniques like machine perfusion and extended criteria grafts.Learn about new transplant indications, including oncology and acute liver failure.Understand challenges in immunosuppression and the management of chronic rejection.FacultyAhmed Elsharkawy (Moderator)Didier Samuel (Faculty)Julie Heimbach (Faculty)Sarwa Darwish (Faculty)Related episodesEASL Studio S4E13: JHEP Live: Liver transplantation for alcohol-related hepatitisEASL Studio S4E6: Regenerating the liver graft with a machineEASL Studio S3E2: Liver transplantation for ACLF: Opportunities, challenges, and pitfallsEASL Studio S3E8: Transplanting patients with cancer – Is there a limit?All EASL Studio Podcasts are available on EASL Campus.

This episode is organised in collaboration with the Healthy Livers, Healthy Lives Coalition.FacultyJeffrey Lazarus (Moderator)Mazen Noureddin (Faculty)Shira Zelber-Sagi (Faculty)Kremlin Wickramasinghe (Faculty)The Healthy Livers, Healthy Lives Coalition’s activities are supported by Boehringer Ingelheim, Echosens, MSD, and Novo Nordisk.Our industry partners have had no input into the content of the Health Livers, Healthy Lives Coalition’s activities or this EASL Studio episode.Related episodesEASL Studio at the Congress 2024: MASLD anno 2024: A rapidly changing landscapeEASL Studio S6E7: The impact of policy measure in preventing liver diseases: The Hepahealth II studyEASL Studio S6E1: Do we solve MASLD by treating obesity?EASL Studio S5E2: Are 30% of the global population sick? A critical view on Steatotic Liver Disease and care pathwaysEASL Studio S4 Special Edition 2: Promoting Liver Health: An urgent call for action at WHOEASL Studio S4E8: The central role of alcohol and food policies on liver healthAll EASL Studio Podcasts are available on EASL Campus.

This episode explores the latest developments in liver disease, with a focus on metabolic-associated steatotic liver disease (MASLD) and its impact on liver cancer, particularly hepatocellular carcinoma (HCC). The main focus is the emerging role of advanced imaging technologies. The discussion:Compares traditional ultrasound with advanced imaging techniques.Examines AI-based approaches in patient classification.The episode concludes with a forward-looking perspective on the future management of MASLD.FacultyThomas Berg (Moderator)Timm Denecke (Faculty)Juan-Manuel Pericàs (Faculty)Valérie Vilgrain (Faculty)This EASL Studio is supported by Bayer. EASL has received no input from Bayer with regards to the content of this programme.Related episodesEASL Studio at the Congress 2024: MASLD anno 2024: A rapidly changing landscapeEASL Studio S6E1: Do we solve MASLD by treating obesity?EASL Studio S4 Special Edition 1: A new strategy for liver cancer screening: EASL Policy Statement on risk-based surveillanceAll EASL Studio Podcasts are available on EASL Campus.

Renal dysfunction is a significant concern for patients with liver cirrhosis, affecting nearly 50% of those hospitalised and leading to various complications that can reduce survival rates. Recently, the diagnostic criteria for acute kidney injury (AKI) and hepatorenal syndrome (HRS) have been updated to better capture the diversity and incidence of these conditions in cirrhotic patients.This episode of EASL Studio:Explores the updated definitions and standardisation of AKI in the context of cirrhosis.Reviews recent clinical trials, including ATTIRE and CONFIRM, and their implications for patient care.Provides a critical analysis of current and emerging strategies for managing renal dysfunction in cirrhosis.FacultyDebbie Shawcross (Moderator)Pere Gines (Faculty)Salvatore Piano (Faculty)Florence Wong (Faculty)Related episodesEASL Studio from EASL Congress 2024: Deciphering the drivers of cirrhosis decompensation: Opportunities for intervention and preventionEASL Studio S6E8: Is there a role for measuring blood ammonia in patients with cirrhosis?EASL Studio S6E5: JHEP Live: Should the compensated advanced chronic liver disease (cACLD) concept replace cirrhosis?EASL Studio S5E11: Statins in cirrhosis: The window hypothesis again, or just a closed window?EASL Studio from EASL Congress 2023: Liver cirrhosis in 2023: Unmet needs and how to address themEASL Studio S4E17: Albumin in Cirrhosis: For all, some, or none?This episode is sponsored by Mallinckrodt Pharmaceuticals. Mallinckrodt Pharmaceuticals have had no input into the content of this EASL Studio episode.All EASL Studio Podcasts are available on EASL Campus.

Arrivederci Milano, hallo Amsterdam!FacultyAleksander Krag (Moderator)Debbie Shawcross (Moderator)Cyrielle Caussy (Faculty)Ana Lleo (Faculty)Francesco Negro (Faculty)Vlad Ratziu (Faculty)Virginia Hernández-Gea (Faculty)All EASL Studio Podcasts are available on EASL Campus.

EASL Studio - Education at the heart of EASL’s missionFacultySven Francque (Moderator)Krista Rombouts (Faculty)Rajeshwar Mookerjee (Faculty)Henning Grønbæk (Faculty)All EASL Studio Podcasts are available on EASL Campus.

EASL Studio - Landmark studies at the EASL Congress 2024FacultyThomas Berg (Moderator)Rajiv Jalan (Faculty)Verena Keitel (Faculty)Frank Tacke (Faculty)All EASL Studio Podcasts are available on EASL Campus.